J&J downgrades biosimilar threat as Q3 pulls in $10bn+ in pharma sales
J&J reported its sixth consecutive quarter with sales above $10 billion in its pharmaceutical division and has lowered its biosimilar headwind forecast to $2 billion. For the third quarter 2019, Johnson & Johnson (J&J) reported sales across all its units of $20.7 billion (€18.8 bill ...
Process development (PD) is a vital CDMO function and one that Avid will continue to invest in, the firm says as it opens a multi-million-dollar ...
In a big week for Big Pharma M&A, Alexion has agreed to buy Factor D inhibitor developer Achillion and UCB will add a late-stage FcRn targeti ...
French drugmaker Sanofi Genzyme has completed process qualification runs at a plant in Framingham based on digital and continuous biologics produ ...
Merck KGaA unit MilliporeSigma has boosted its CAR-T autologous manufacturing services by buying FloDesign Sonics, adding an acoustic cell proces ...
Recent Tweets
-
RT @Dan5tanton: Sanofi Genzyme has completed process qualification runs at a plant in Framingham based on digital and continuous bi… https://t.co/MpTBA5IxKk
2 days ago
-
RT @Dan5tanton: Lonza CEO Marc Funk says the #CDMO will take a pragmatic approach to expanding its position from "timid actor" to m… https://t.co/U82uduWDoM
3 days ago
-
RT @BioProcessIntl: The New Era of Emerging Therapies Webinar Series
Oct. 29-30 presented by @Xconomy
CRISPR in t… https://t.co/1AKlSbPLbC
1 week ago
-
RT @Dan5tanton: Having recently invested over $1.6 billion in its network, Merck says it is committed to further expand the supply… https://t.co/vhCxMYVTMx
2 weeks ago
